AMAG Pharmaceuticals — FY2018 Earnings Presentation
29 slides from AMAG Pharmaceuticals's earnings presentation, Feb 7, 2019
Slide 1: AMAG Pharmaceuticals 2018 Financial Results & Company Update
AMAG Pharmaceuticals 2018 Financial Results & Company Update February 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, the
Slide 3: Agenda
Agenda 1 2018 Accomplishments 2 Commercial Product Portfolio Update 3 Development Product Portfolio Update – Focus on Ciraparantag 4 Financial Overview 5 Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 3
Slide 4: 2018 Accomplishments
2018 Accomplishments Intrarosa® (prasterone) . Established strong healthcare provider support . Initiated direct-to-consumer campaign VyleesiTM (bremelanotide) . FDA acceptance of new drug application (NDA) . Initiated frequent dosing study in healthy volunteers Makena® (hydroxyprogesterone capr
Slide 5: Achieved 2018 Financial Objectives
Achieved 2018 Financial Objectives Increased financial guidance three times throughout 2018 Preliminary Results ($M) 2018 Issued Guidance1,3 Issued in January 2019 January 2018 May 2018 August 2018 November 2018 FY 2018 Total revenue $380 - $440 $420 - $460 $450 - $490 $470 - $490 $471 - $476 Operat
Slide 6: Historical Value Drivers
Historical Value Drivers HISTORICAL Value of AMAG © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 6
Slide 7: Feraheme Continues to Grow with Expanded Label
Feraheme Continues to Grow with Expanded Label Annual Feraheme Revenue ($M) Feraheme Growth • Strong execution with expanded lDA label drove 27% significant volume increases in 2018 – Performance-based contracting drove volume, with stable annual price • Q4-2018 average market share rose to 16.6%, c
Slide 8: Continued Strong Conversion from Makena IM to SC Auto-injector
Continued Strong Conversion from Makena IM to SC Auto-injector Annual Makena Revenue ($M) Makena Stability • Q4-2018 SC auto-injector – Achieved $35M revenue • Ex-factory sales impacted by a reduction in channel inventory levels at year end due to temporary supply constraints, which are now resolved
Slide 9: Significant Shareholder Value at AMAG
Significant Shareholder Value at AMAG Historical Value Drivers Fund Future Value Drivers ciraparantag AMAG-423 Fundingfunding HISTORICAL Value of AMAG FUTURE Value of AMAG Historical Value Drivers Fund Future Value Drivers © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 9
Slide 10: Intrarosa HCP Prescribing and Market Share Continue to Increase
Intrarosa HCP Prescribing and Market Share Continue to Increase Direct-to-Consumer (DTC) campaign demonstrating strong patient engagement Annual Intrarosa Revenue ($M) Intrarosa Growth • Strong prescription trends continue2 – 13.6% overall TRx market growth in 2018 – 159,000 TRxs in 2018 – 13,000+ p
Slide 11: Accessing the 90% of Women Who are Not Being Treated with Rx
Accessing the 90% of Women Who are Not Being Treated with Rx 2019 Branded consumer campaign resulting 5 in patients asking for Intrarosa Increase HCP prescribing and make 4 Intrarosa the 1st choice treatment 2018 3 Educate with unbranded condition awareness campaign Create affordable access 2 for al
Slide 12: AMAG's Growing Innovative Pipeline
AMAG's Growing Innovative Pipeline Approved/ Phase 1 Phase 2 Phase 3 Regulatory Review Marketed Ciraparantag Anticoagulant reversal agent (potential for orphan drug designation) Treatment of iron deficiency anemia H E M A T O L O G Y AMAG-423 Treatment of severe preeclampsia Digoxin Immune (orphan d
Slide 13: AMAG Product Development Milestone Calendar
AMAG Product Development Milestone Calendar 1H-2019 2H-2019 1H-2020 2H-2020 1H-2021 2H-2021 June 23 Potential Vyleesi PDUFA date commercial launch 423 - Target complete enrollment in Phase 2b/3a trial Topline data NDA submission Potential FDA approval AMAG End of Phase 2 Complete Phase 1 Closed Pero
Slide 14: Novel Oral Anticoagulant (NOAC) Use Growing
Novel Oral Anticoagulant (NOAC) Use Growing • Anticoagulants (often referred to as blood thinners) reduce the ability of the blood to form clots – Prevention of stroke in patients with nonvalvular atrial fibrillation – Prevention and treatment of deep vein thrombosis and pulmonary embolism – Use of
Slide 15: Ciraparantag: Differentiated Anticoagulation Reversal Therapy
Ciraparantag: Differentiated Anticoagulation Reversal Therapy Well suited for use in emergency room setting Storage & Duration Prothrombotic Reversal Agent Dosing Preparation of Action Signal Praxbind® • Requires storage at • One treatment given as 2 • Sustained effect over • No prothrombotic o o o
Slide 16: Action of Anticoagulants and Ciraparantag in the Blood Clotting Cascade
Action of Anticoagulants and Ciraparantag in the Blood Clotting Cascade Whole Blood Clotting Time (WBCT) is the most clinically relevant measure in healthy volunteers F XII WBCT is currently a manual measure of the time it takes Clotting Cascade for blood to clot – clinically relevant physiologic ou
Slide 17: Phase 2b Study: Reversal of Xarelto
Phase 2b Study: Reversal of Xarelto® Ongoing study in healthy subjects; high dose group demonstrates 100% response rate Ciraparantag or placebo dose 0.0% Baseline & Xarelto® dose WBCT reversed to within 10% n n n n 1 of baseline within 30 minutes Placebo Ciraparantag 60 mg Ciraparantag 120 mg Cirapa
Slide 18: Favorable Safety Profile of Ciraparantag
Favorable Safety Profile of Ciraparantag Ciraparantag was well tolerated in over 250 subjects dosed in Phase 1/2 clinical studies to date • Across Phase 1/2 clinical studies (5 completed studies, 2 ongoing studies) to date – Over 250 healthy adult subjects have received ciraparantag; doses ranged fr
Slide 19: Ciraparantag Path to Approval
Ciraparantag Path to Approval 1H-2019 2H-2019 1H-2020 2H-2020 1H-2021 2H-2021 End of Phase 2 Complete Phase 1 Closed Perosphere NDA submission Potential FDA approval meeting with FDA; 3a trials; acquisition Initiate Phase 3a trials announce topline data Apply for orphan Initiate and breakthrough Pha
Slide 20: Financial Overview
Financial Overview 20
Slide 21: 2018 Financial Results within Guidance Range
2018 Financial Results within Guidance Range For 12-months ended December 311 $M 2018 2017 • Makena decline due to IM generic competition and supply Makena $322.3 $387.2 constraints; partially offset by success of auto-injector launch in Q2-2018 and AGx Feraheme/MuGard 135.4 106.7 Intrarosa 16.2 1.8
Slide 22: Reaffirming 2019 Financial Guidance
Reaffirming 2019 Financial Guidance Published on January 7, 2019 Key inputs and drivers of financial guidance • Spending includes increase in R&D – Completion of Phase 2 development of ciraparantag, initiation ($M) 2019 Financial Guidance1 of Phase 3a trial – Targeting full enrollment of AMAG-423 Ph
Slide 23: Strong Balance Sheet
Strong Balance Sheet ($M) 12/31/18 12/31/17 Cash, cash equivalents and investments $3941 $329 Short-term debt: Convertible senior notes (2.5%) due Feb. 2019 $ 21 $ 21 Long-term debt: Convertible senior notes (3.25%) due 2022 $320 $320 Senior notes (7.875%) due 2023 $ 0 $475 1 $394M cash balance does
Slide 24: Strong Execution Transforms Company Profile in 2019
Strong Execution Transforms Company Profile in 2019 2019 Goals Expand use of Makena SC auto-injector Drive Feraheme growth Continue successful Intrarosa direct-to-consumer campaign Submit Vyleesi frequent-dosing study data Prepare for Vyleesi commercial launch in 2H-2019 Target full enro
Slide 25: AMAG Pharmaceuticals Q&A
AMAG Pharmaceuticals Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 25
Slide 26: Appendix
Appendix 26
Slide 27: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results Preliminary Results Issued in January 2019 $M 2018 2017 2018 GAAP operating income (loss) ($47.0) ($303.8) ($55) - ($45) Depreciation and intangible asset amortization 160.0 131.6 161 Non-cash inventory step-up adjustments 3.7 2.2 4 Stock-based co
Slide 28: Reconciliation of GAAP to Non-GAAP Financial Guidance
Reconciliation of GAAP to Non-GAAP Financial Guidance Guidance Issued ($M) January 2018 May 2018 August 2018 November 2018 January 2019 GAAP operating loss ($169) – ($139) ($149) – ($129) ($75) - ($55) ($72) - ($62) ($131) – ($101) Depreciation & intangible asset amortization 179 179 174 177 43 Stoc
Slide 29: AMAG Pharmaceuticals 2018 Financial Results & Company Update
AMAG Pharmaceuticals 2018 Financial Results & Company Update February 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 29